As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...
Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...
Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
Nolan married her husband of more than two decades, Brian Hudson, in the Blackpool church, and said goodbye to him there ...
Singer Linda Nolan was brought to her funeral in a pink sparkly coffin as a large crowd of family and friends gathered in ...
2hon MSN
Linda Nolan's funeral will be held today as her family and friends celebrate her "remarkable life". Members of the public are welcome to pay their respects at the church for the service at 10.30am on ...
Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...
Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer: Tokyo Saturday, February 1, 2025, 12:30 Hrs [IST] ...
The Nolans star, known by many TV fans for her Celebrity Big Brother appearance and by others as a theatre performer, was ...
The Swiss pharmaceutical company said the FDA backed a label expansion for the Pathway HER2 (4B5) test to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who could be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback